Table 2.
Body weight and AGEs Levels.
| Group | Treatment | Body weight | Serum AGEs (ng/mL) | Cerebral AGEs (ng/mg prot) | |
|---|---|---|---|---|---|
| Pretreatment | Posttreatment | ||||
| I | Young control | 22.83 ± 1.13 | 25.32 ± 1.15 | 145.34 ± 47.73 | 24.71 ± 23.42 |
| II | D-gal (100 mg/kg) | 22.62 ± 0.98 | 23.93 ± 0.98 | 294.65 ± 165.93* | 53.46 ± 29.57* |
| III | D-gal + PP (500 mg/kg) | 22.37 ± 0.80 | 23.28 ± 1.00 | 163.47 ± 158.04∆ | 31.46 ± 14.86 |
| IV | D-gal + PP (1000 mg/kg) | 21.84 ± 0.93 | 22.99 ± 1.42 | 201.69 ± 118.65 | 31.67 ± 18.65 |
| V | D-gal + PP (1500 mg/kg) | 22.13 ± 1.46 | 23.52 ± 1.80 | 202.08 ± 158.40 | 27.71 ± 19.06∆ |
| VI | D-gal + AG (100 mg/kg) | 22.32 ± 1.32 | 24.63 ± 2.05 | 158.29 ± 101.17∆ | 23.88 ± 19.17∆ |
Note. C57BL/6J female mice (5-month-old, n = 10 in each group) were treated daily with PBS (s.c, young control), D-galactose (D-gal, 100 mg/kg, s.c), D-gal (100 mg/kg, s.c) with pine pollen (PP, 500, 1000, 1500 mg/kg, ig) and aminoguanidine (AG, 100 mg/kg, ig). AGEs levels at the end of the treatment were determined by a quantitative AGEs-ELISA kit. Statistical significant difference: *P < 0.05, versus I; ∆ P < 0.05, versus II.